期刊文献+

重型再生障碍性贫血患者混合血清对转染Jak2v617f小鼠32D细胞的影响 被引量:1

下载PDF
导出
摘要 目的观察小鼠32D细胞转染Jak2v617f后,重型再生障碍性贫血(SAA)患者混合血清对其增殖、凋亡能力及细胞周期的影响。方法实验分4组:32D组及32D+SAA组,即未感染病毒的32D细胞分别与正常混合血清或SAA患者混合血清培养;32D+Jak2v617f组及32D+Jak2v617f+SAA组,即感染上Jak2v617f慢病毒的32D细胞分别与正常混合血清或SAA患者混合血清培养。用MTS法检测4组细胞的增殖能力;利用流式细胞仪检测细胞凋亡能力及细胞周期的变化。结果与32D组比较,32D+Jak2v617f组48、72 h时细胞增殖能力增强(P<0.01);32D+SAA组48、72 h时细胞增殖受到抑制(P<0.05,P<0.01),而32D+Jak2v617f+SAA组细胞增殖也受抑制并恢复至32D组水平(P>0.05)。流式细胞仪检测发现32D+SAA组晚期凋亡细胞增多;相反地,32D+Jak2v617f组早、晚期凋亡细胞均减少;32D+Jak2v617f+SAA组早、晚期凋亡细胞也减少,但减少程度不如32D+Jak2v617f组。32D+SAA组以G_1期细胞比例最高,为73.55%,S期为20.72%;32D+Jak2v617f组则相反,G_1期细胞比例最少,为40.04%,S期细胞比例则最高,为53.83%;32D+Jak2v617f+SAA组则与32D组相仿。结论Jak2v617f基因可能通过减少细胞凋亡、增强DNA复制的S期而提高细胞的增殖能力;SAA患者混合血清则与之相反,并可能遏制Jak2v617f基因的这种增殖趋势。
出处 《广东医学》 CAS 北大核心 2015年第22期3434-3437,共4页 Guangdong Medical Journal
基金 广东省科技计划项目(编号:2011B031800344)
  • 相关文献

参考文献8

  • 1ALEXANDRA D C, LINE M, CHRISTIAN P, et al. JAK2 V617F Constitutive Activation Requires JI-I2 Residue F595: A Pseudoki- nase Domain Target for Specific Inhibitors[ J. PLoS One, 2010, 5(6): e11157.
  • 2KRALOVICS R, TEO S S, BUSER A S, et al. Altered gene ex- pression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 [ J ]. Blood, 2005, 106 (10) : 3374 -3376.
  • 3XING L, DAI Z, JABBARI A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition[ J]. Nat Med, 2014, 20(9): 1043-1049.
  • 4PARK J S, LEE J, LIM M A, et al. JAK2 - STAT4 blockade by AG490 suppresses autoimmune arthritis in mice via reciprocal reg- ulation of regulatory T Ceils and Thl7 cells [ J ]. J Immunol, 2014, 192(9) : 4417 -4424.
  • 5CHOI J, COOPER M L, ALAHMARI B, et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserws the graft - versus -leukemia effect[ J. PLoS One, 2014, 9 (10) : e109799.
  • 6林赠华,刘红,姜胜华,陆伟,宋国齐,李俊宏.非重型再生障碍性贫血患者血清对32D细胞凋亡及Stat3蛋白磷酸化的影响[J].山东医药,2011,51(37):16-18. 被引量:2
  • 7WELSH J P, RUTHERFORD T R, FLYNN J, et al. In vitro effects of interfer - on - gamma and tumor necrosis factor - alpha on CD + 34 bone marrow progenitor ceUs from aplastic anemia pa- tients and normal donors [ J ]. Hematol J, 2004, 5 ( 1 ) : 39 - 46.
  • 8GAUTIER E F, PICARD M, LAURENT C, et al. The cell cycle regulator CDC25A is a target for JAK2V617F oncogene [ J ]. Blood, 2012, 119(5): 1190-1199.

二级参考文献12

  • 1Welsh JP,Rutherford TR,Flynn J,et al.In vitro effects of interferon-gamma and tumor necrosis factor-alpha on CD3+34 bone marrow progenitor cells from aplastic anemia patients and normal donors[J].Hematol J,2004,5(1):39-46.
  • 2Hankey PA.Regulation of hematopoietic cell development and function by Stat3[J].Front Biosci,2009,14:5273-5290.
  • 3Snyder M,Huang XY,Zhang JJ.Stat3 directly controls the expression of Tbx5,Nkx2.5,and GATA4 and is essential for cardiomyocyte differentiation of P19CL6 cells[J].J Biol Chem,2010,285(31):23639-23646.
  • 4Johnston PA,Grandis JR.STAT3 signaling:anticancer strategies and challenges[J].Mol Interv,2011,11 (1):18-26.
  • 5Bai YL,Ahmad U,Wang Y,et al.Intefferon-γ induces X-linked inhibitor of apopt0eis-associated factor-1 and noxa expression and potentiates human vascular smooth muscle cell apoptosis by STAT3 activation[J].J Biol Chem,2008,283(1 1):6832-6842.
  • 6Zaragozá R,Bosch A,García C,et al.Nitric oxide triggers mammary gland involution after weaning:remodelling is delayed but not impaired in mice lacking inducible nitric oxide synthase[J].Biochem J,2010,428(3):451-462.
  • 7Yang L,Dybedal I,Bryder D,et al.IFN-gamma negatively modulates self-renewal of repopulating human hemopoietic stem cells[J].J Immunol,2005,174(2):752-757.
  • 8林赠华,刘红,李俊宏,姜胜华,丁润生,陆伟,蔡奕峰,宋国齐.重型再生障碍性贫血患者血清对小鼠造血干/祖细胞株32D细胞凋亡和Stat3、Stat5分子表达的影响[J].中华血液学杂志,2009,30(11):767-769. 被引量:3
  • 9杨小飞,刘红,钱军,姜胜华.再生障碍性贫血患者血清对小鼠髓系前体细胞凋亡及蛋白激酶B表达的影响[J].山东医药,2010,50(11):4-6. 被引量:3
  • 10上海地区成人获得性再生障碍性贫血患者诊断和治疗现状——附142例分析[J].中华血液学杂志,2010,31(4):275-278. 被引量:4

同被引文献17

  • 1Jan Jacques Michiels,Fibo Ten Kate,King H Lam,et al. The European clinical,molecular,and pathological (ECMP) criteria and the 2007/2008 revisions of the World Health Organization for the diagnosis, classification, and staging of prefihrotic myeloproliferative neoplasms carrying the JAK2V617F mutation[J]. Turk J Haematol, 2014,31 (3) : 239-254.
  • 2Camilla Nielsen,Stig E Bojesen,Bcrge G,et al. JAK2V617F somatic mutation in the general population:Myeloprolifer ative neoplasm development and progression rate[J].Haema- tologica, 2014,99(9) : 1448-1455.
  • 3Scheinberg P. Aplastic anemia:therapeutic updates in im- munosuppression and transplantation[J]. Hematology Am Soc Hematol Educ Program, 2012,2012: 292-300.
  • 4Seung Hwan Shin,Sung Eun Lee,Jong Wook Lee. Recent advances in treatment of aplastic anemia[J]. Korean J In- tern Med,2014,29(6) :713-726.
  • 5Qingqing Wu,Jizhou Zhang,Jun Shi,et al. Increased bone marrow (BM) plasma level of soluble CD30 and correla- tions with BM plasma level of interferon (IFN)-γ,CD4/CD8 T-cell ratio and disease severity in aplastic anemia[J]. PLoS One, 2014,9 ( 11 ) : e 110787.
  • 6Alexandra D,Cline M,Christian P,et al. JAK2 V617F constitutive activation requires JH2 residue F595:A pseu dokinase domain target for specific inhibitors[J]. PLoS One, 2010,5(6) :e11157.
  • 7Williams DM, Kim AH, Rogers O, et al. Phenotypic varia- tions and new mutations in JAK2 V617F-negative poly cythemia vera,erythrocytosis,and idiopathic myelofibrosis[J]. Exp Hematol, 2007,35 ( 11 ) : 1641-1646.
  • 8Xingmin Feng, Phillip Scheinberg, Colin 0 Wu, et al. Cy- tokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes[J]. Haematologica, 2011, 6(4) : 602-606.
  • 9Bogeska R,Pahl HL. Elevated nuclear factor erythroid-2 levels promoteepo-independent erythroid maturation and recapitulate the hematopoietic stem cell and co mmon myeloid progenitor expansion observed in polypoly- cythemia vera patients[J]. Stem Ceils Transl Med, 2013,2 (2):112-117.
  • 10Ye Z, Liu CF, Lanikova L, et al. Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient- specific induced pluripotent stem cells[J]. Stem Cells, 2014,32(1) : 269-278.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部